Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis

Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis

About 5% of chronic hepatitis C (CHC) patients experienced treatment failure with direct-acting antiviral (DAA) treatment. The global data on the practice and treatment outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in DAA-experienced CHC patients remains sparse. We performed a system...

Full description

Bibliographic Details
Main Authors: Pooja Devan, Kai Le Ashley Tiong, Jean Ee Neo, Babu P. Mohan, Karn Wijarnpreecha, Yew Chong Steve Tam, Nicola Coppola, Carmen Monica Preda, Yu Jun Wong
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Viruses
Subjects:
direct-acting antiviral
treatment
ribavirin
sustained virological response
adverse effects
HCV genotype
Online Access:https://www.mdpi.com/1999-4915/15/7/1489

Internet

https://www.mdpi.com/1999-4915/15/7/1489

Similar Items